tiprankstipranks
MyMD Pharmaceuticals (MYMD)
NASDAQ:MYMD

MyMD Pharmaceuticals (MYMD) Stock Price & Analysis

521 Followers

MYMD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.23 - $70.50
Previous Close$2.35
Volume32.98K
Average Volume (3M)51.55K
Market Cap
$4.92M
Enterprise Value-$3.48M
Total Cash (Recent Filing)$8.47M
Total Debt (Recent Filing)$72.63K
Price to Earnings (P/E)-0.4
Beta1.54
May 20, 2019
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-5.56
Shares Outstanding2,091,638
10 Day Avg. Volume25,823
30 Day Avg. Volume51,551
Standard Deviation0.33
R-Squared0.14
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

MYMD FAQ

What was MyMD Pharmaceuticals’s price range in the past 12 months?
MyMD Pharmaceuticals lowest stock price was $2.23 and its highest was $70.50 in the past 12 months.
    What is MyMD Pharmaceuticals’s market cap?
    Currently, no data Available
    When is MyMD Pharmaceuticals’s upcoming earnings report date?
    MyMD Pharmaceuticals’s upcoming earnings report date is May 20, 2019 which is 1775 days ago.
      How were MyMD Pharmaceuticals’s earnings last quarter?
      MyMD Pharmaceuticals released its earnings results on Apr 01, 2019. The company reported -$3.526 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.526.
        Is MyMD Pharmaceuticals overvalued?
        According to Wall Street analysts MyMD Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does MyMD Pharmaceuticals pay dividends?
          MyMD Pharmaceuticals does not currently pay dividends.
          What is MyMD Pharmaceuticals’s EPS estimate?
          MyMD Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does MyMD Pharmaceuticals have?
          MyMD Pharmaceuticals has 2,091,638 shares outstanding.
            What happened to MyMD Pharmaceuticals’s price movement after its last earnings report?
            MyMD Pharmaceuticals reported an EPS of -$3.526 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of MyMD Pharmaceuticals?
              Currently, no hedge funds are holding shares in MYMD
              ---

              MyMD Pharmaceuticals Stock Smart Score

              Company Description

              MyMD Pharmaceuticals

              Akers Biosciences, Inc. develops health information technologies. It engages in the developing, manufacturing, and supplying screening and testing products to deliver healthcare information to consumers and healthcare providers. Its products include clinical diagnostics, safety diagnostics, wellness products, and tests in development. The company was founded by Raymond Francis Akers, Jr. and Raymond F. Akers, Sr. on March 8, 1989 and is headquartered in West Deptford, NJ.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Akari Therapeutics
              BioCryst
              Cytokinetics
              Xenon
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis